$FOLD Company News La-Z-Boy shares rally after earnings

New Post Public Reply Private Reply Replies (0) Message Board

Jan 20, 2015 at 9:32 AM

$FOLD Company News

La-Z-Boy shares rally after earnings beat targets 4:41 p.m. Nov. 18, 2014 - Sue Chang
Urban Outfitters slides after earnings miss expectations 4:43 p.m. Nov. 17, 2014 - Sue Chang
Apple sets intraday record; PetSmart considers sale 12:56 p.m. Aug. 20, 2014 - Ben Eisen
Amicus Therapeutics shares up 25.6% in premarket trade 7:05 a.m. Aug. 20, 2014 - Ciara Linnane
Amicus Therapeutic’s Fabry treatment meets goals in late-stage trial 7:04 a.m. Aug. 20, 2014 - Michael Calia
U.S. stocks rise as risk appetite returns 4:19 p.m. April 29, 2014 - Anora Mahmudova
Twitter rallies ahead of earnings; 3D Systems retreats 2:49 p.m. April 29, 2014 - Sue Chang
U.S. stock futures climb; House prices flat in February 8:19 a.m. April 29, 2014 - Barbara Kollmeyer
Amicus rallies 52% premarket after positive trial results 6:25 a.m. April 29, 2014 - Sara Sjolin
Amicus rallies 52% premarket after positive trial results 6:08 a.m. April 29, 2014 - Sara Sjolin
Amicus stock down after it delays seeking Fabry OK 9:44 a.m. June 17, 2013 - MarketWatch.com
Friday’s biggest gaining and declining stocks 9:45 a.m. Jan. 4, 2013 - Greg Morcroft
Amicus Therapeutics up 11% in premarket 7:52 a.m. Jan. 4, 2013 - Steve Gelsi
Thursday’s movers: Apple ends in red on price cut 5:03 p.m. Dec. 20, 2012 - Sue Chang
Amicus down 45% in premarket 8:44 a.m. Dec. 20, 2012 - Steve Gelsi
Amicus falls 47% in premarket trades 7:52 a.m. Dec. 20, 2012 - Steve Gelsi
Bed Bath shares hurt, Jabil climbs after hours 6:31 p.m. Dec. 19, 2012 - Carla Mozee
Amicus, GlaxoSmithKline say treatment misses goal 5:22 p.m. Dec. 19, 2012 - MarketWatch.com
Amicus Therapeutics shares tumble 49% after hours 4:45 p.m. Dec. 19, 2012 - Carla Mozee
U.S. Hot stocks to watch 6:28 a.m. July 18, 2012 - MarketWatch.com

Amicus Therapeutics (FOLD) Weak On High Volume 10:03 a.m. Jan. 9, 2015 - TheStreet.com
Biotech Investors Guide and Preview to the J.P. Morgan Healthcare Conference Part 1 1:09 p.m. Jan. 8, 2015 - TheStreet.com
Migalstat HCL has positive impact on cardiac endpoint in Fabry study 11:31 a.m. Jan. 8, 2015 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Knowing Where to Look for Bargains 8:25 p.m. Jan. 6, 2015 - TheStreet.com
Use Options For A Chance To Buy FOLD At A 33% Discount 11:47 a.m. Dec. 31, 2014 - TheStreet.com
One Dad’s 14-Year Quest for Children’s Cure 7:25 p.m. Dec. 26, 2014 - The Wall Street Journal Interactive Edition
Amicus: Multiple Catalysts For Promising Fabry Treatment 12:01 p.m. Dec. 24, 2014 - Seeking Alpha
Trade-Ideas: Amicus Therapeutics (FOLD) Is Today's "Perilous Reversal" Stock 10:02 a.m. Dec. 23, 2014 - TheStreet.com
NPS Pharmaceuticals Spikes 19% Amid Shire Bid Report 10:15 a.m. Dec. 17, 2014 - benzinga.com
Nasdaq makes annual changes to Biotechnology Index 12:36 p.m. Dec. 15, 2014 - Seeking Alpha
Will Amicus Therapeutics (FOLD) Continue to Surge Higher? - Tale of the Tape 9:41 a.m. Dec. 2, 2014 - Zacks.com
Amicus Therapeutics (FOLD) Weak On High Volume 10:00 a.m. Dec. 1, 2014 - TheStreet.com
InsiderInsights.com Daily Round Up 11/25/14: AAPL, FCF, AVID, SC 1:20 a.m. Nov. 26, 2014 - Seeking Alpha
Warren Buffett Pick CBI Tumbles On Rating Downgrade 1:00 p.m. Nov. 24, 2014 - TheStreet.com
BioMarin Buying Prosensa, Backing Up Troubled Drug 9:22 a.m. Nov. 24, 2014 - Investors Business Daily
InsiderInsights.com Daily Round Up 11/19/14: CJES, MGPI, PSX, STAA 2:58 a.m. Nov. 20, 2014 - Seeking Alpha
Amicus prices stock offering 7:13 a.m. Nov. 19, 2014 - Seeking Alpha
Amicus' Migalastat Should Have Smooth Sailing To FDA And European Approval For Fabry Disease 9:47 a.m. Nov. 18, 2014 - Seeking Alpha
Amicus Therapeutics, Inc. (FOLD) in Focus: Stock Soars 17.8% - Tale of the Tape 9:21 a.m. Nov. 18, 2014 - Zacks.com
Market News: Amicus Therapeutics, Urban Outfitters, Ford 5:08 p.m. Nov. 17, 2014 - TheStreet.com

Amicus Therapeutics Announces Positive Phase 3 Data on Cardiac Endpoints From Fabry Monotherapy Study 011 and Long Term Extension Study 7:31 a.m. Jan. 8, 2015 - GlobeNewswire
Amicus Therapeutics to Present Program Updates at 33rd Annual J.P. Morgan Healthcare Conference 7:30 a.m. Dec. 22, 2014 - GlobeNewswire
Amicus Therapeutics Added to NASDAQ Biotechnology Index (NBI) 7:30 a.m. Dec. 22, 2014 - GlobeNewswire
Annual Changes to the NASDAQ Biotechnology Index 7:10 a.m. Dec. 15, 2014 - GlobeNewswire
Amicus Therapeutics to Submit European Marketing Application for Migalastat Monotherapy for Fabry Disease 7:31 a.m. Dec. 11, 2014 - GlobeNewswire
Amicus Therapeutics to Present at Oppenheimer Healthcare Conference 4:01 p.m. Dec. 4, 2014 - GlobeNewswire
Biotech Stocks Technical Coverage - OPKO Health, IsoRay, Nanosphere, Amicus Therapeutics, and Isis Pharma 8:50 a.m. Dec. 4, 2014 - PR Newswire - PRF
Amicus Therapeutics Announces Closing of Underwritten Offering of Common Stock and Full Exercise of Over-Allotment Option 4:00 p.m. Nov. 24, 2014 - GlobeNewswire
Amicus Therapeutics Prices Underwritten Offering of Common Stock 7:16 p.m. Nov. 18, 2014 - GlobeNewswire
Amicus Therapeutics Announces Public Offering of Common Stock 4:01 p.m. Nov. 17, 2014 - GlobeNewswire
Amicus Therapeutics Announces Positive Phase 3 Data on Cardiac and Composite Endpoints from Fabry Monotherapy Study 012 at American Society of Nephrology 10:01 a.m. Nov. 15, 2014 - GlobeNewswire
Amicus Therapeutics Announces Third Quarter 2014 Financial Results and Corporate Updates 4:01 p.m. Nov. 6, 2014 - GlobeNewswire
Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 7:45 a.m. Oct. 22, 2014 - PR Newswire - PRF
Amicus Therapeutics Announces Additional Positive Phase 3 Data From Fabry Monotherapy Study 011 6:00 p.m. Oct. 19, 2014 - GlobeNewswire
Amicus Therapeutics to Present at Leerink Partners Rare Disease Roundtable 8:30 a.m. Sept. 30, 2014 - GlobeNewswire
Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 7:40 a.m. Sept. 12, 2014 - PR Newswire - PRF
Clinical Trial Results, Change of Corporate Name, New Products, and Completion of Acquisition - Research Reports on GSK, Amicus, WellPoint, IDEXX and Endo 7:40 a.m. Aug. 25, 2014 - PR Newswire - PRF
Amicus Therapeutics Announces Positive Phase 3 Data From Fabry Monotherapy Study 012 5:00 a.m. Aug. 20, 2014 - GlobeNewswire
Pre-Market Review on Biotech Equities -- Exelixis, Novavax, Achillion Pharma, XOMA, and Amicus Therapeutics 7:50 a.m. Aug. 13, 2014 - PR Newswire - PRF
Amicus Therapeutics Announces Second Quarter 2014 Financial Results and Corporate Updates 3:01 p.m. Aug. 7, 2014 - GlobeNewswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

DIRECTV Bags New NHL Deals: Stakes for Sports Fans

NHL Fans, Strap in: DIRECTV Expands Its Lineup In a world where keeping up with your favorite team gets tougher each day, DIRECTV just lobbed a puck right into the net with their latest play. They've snagged a multi-year deal with the NHL for the Carolina Hurricanes, Columbus Blue Jackets, Minnesota Wild, and St. Louis Blues networks. It's a game changer, folks. If you...

Spooky Dining at CARNE: A Halloween Hit in Oxnard

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Fluence Energy Hits Legal Snag: Investors Called to Act

Fluence Energy Faces a Securities Fraud Challenge It's like watching a slow-motion train wreck. Fluence Energy, Inc. (NASDAQ: FLNC) now finds itself in the crosshairs of a securities fraud class action lawsuit. Apparently, someone was playing fast and loose with the truth concerning their financial guidance. The period in question stretches from November 24, 2025, to...

Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Monster Energy Unleashes Gaming Frenzy at Cosm L.A. Event

Where Energy Drinks and Digital Reality Collide Monster Energy sure knows how to throw a party, especially when it hinges on something as electrifying as Call of Duty: Modern Warfare 4. Imagine this: Cosm Los Angeles is decked out with a massive 87-foot LED dome, and every gamer, celeb, and influencer ready to dive right in. You can't make this stuff up. They've mashed...

Community in Shock After Fatal Bakersfield Shooting

The Ripple Effect of Tragedy Grief has a way of shaking a community down to its core—especially when the loss emanates from such senseless violence as the shooting death of 17-year-old Levi Brown. This wasn't just a tragic occurrence at a Friday night football game in Bakersfield; it was a visceral crack in the perceived safety of community events. Levi's Legacy and...

Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Innovent's IBI3001 Shows Promise in Phase 1 Trials

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Axon Body 5: A Leap Forward in AI for Public Safety

Axon Raises the Stakes with Body 5 Camera Boy, oh boy, Axon's dropped a bombshell with the Body 5. We're talking a colossal leap into the AI era for public safety, and if you're in the biz, you can't just shrug this one off. We're looking at 25 times the AI processing power compared to Axon's old units. That's right, I said twenty-five. Real-time situational awareness in...